Stockreport

FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer

IceCure Medical Ltd. - Ordinary Shares  (ICCM) 
PDF FDA decision on marketing authorization expected in the first quarter of 2025CAESAREA, Israel, Nov. 8, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure [Read more]